ClinicalTrials.gg
CompletedNCT03100942Updated Oct 23, 2020Results posted

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

A Phase 2 interventional study of Lanraplenib and Filgotinib in Sjogren's Syndrome, sponsored by Gilead Sciences. Completed at 53 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
24th of 76
152 · median 57
Started
2017
with 4 others
Phase 2
30 of 111
3 open now
Registered
52nd of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 24th largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2017, is one of 30 in phase 2, and was the 52nd registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).

03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with primary or secondary SjS according to the 2002 American European Consensus Group (AECG) classification
  • Active SjS as defined by an European League Against Rheumatism (EULAR) Sjogren's syndrome disease activity index (ESSDAI) ≥ 5
  • Seropositivity for antibodies to SjS-associated antigens A and/or B (anti-SSA or anti-SSB)

Key Exclusion Criteria:

  • Concurrent treatment with any biologic disease modifying antirheumatic drug (bDMARD) (prior bDMARD treatment allowed with appropriate as per study protocol)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Lanraplenib

    Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.

    Drug: Lanraplenib · Drug: Filgotinib placebo · Drug: Tirabrutinib placebo

  • Experimental
    Filgotinib

    Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.

    Drug: Filgotinib · Drug: Lanraplenib placebo · Drug: Tirabrutinib placebo

  • Experimental
    Tirabrutinib

    Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.

    Drug: Tirabrutinib · Drug: Lanraplenib placebo · Drug: Filgotinib placebo

  • Placebo comparator
    Placebo, then active treatment

    Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48: * filgotinib + lanraplenib placebo + tirabrutinib placebo * lanraplenib + filgotinib placebo + tirabrutinib placebo * tirabrutinib + filgotinib placebo + lanraplenib placebo

    Drug: Lanraplenib · Drug: Filgotinib · Drug: Tirabrutinib · Drug: Lanraplenib placebo · Drug: Filgotinib placebo · Drug: Tirabrutinib placebo

Interventions

  • 1 x 30 mg tablet administered orally once daily

    Also known as: GS-9876

  • 1 x 200 mg tablet administered orally once daily

    Also known as: GS-6034

  • 1 x 40 mg tablet administered orally once daily

    Also known as: GS-4059

  • DrugLanraplenib placebo

    1 x tablet administered orally once daily

  • DrugFilgotinib placebo

    1 x tablet administered orally once daily

  • DrugTirabrutinib placebo

    1 x tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline

    Response was defined as: Improvement ≥ 20% in ≥ 3 of 5 participant-reported Sjogren's syndrome (SjS) related visual analogue score (VAS) measures (participant's assessment of global disease, pain, oral dryness, ocular dryness and fatigue), with no increase defined as \> 30 mm from baseline (Day 1) in any of the above 5 VAS measures, AND either ≥ 20% improvement in high sensitivity C-reactive protein (hsCRP) (if hsCRP ≥ 1.5 x upper limit of normal \[ULN\] on Day 1) or no increase in hsCRP to ≥ 1.5 x ULN (if hsCRP \< 1.5 x ULN on Day 1).

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12

    The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.

    Time frame: Baseline; Week 12

  2. Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12

    The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.

    Time frame: Baseline; Week 12

  3. Change From Baseline in ESSDAI at Week 24

    The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.

    Time frame: Baseline; Week 24

  4. Change From Baseline in ESSPRI at Week 24

    The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.

    Time frame: Baseline; Week 24

07

Results

Posted Jan 22, 2020
Limitations and caveats
An unplanned review of unblinded clinical trial data was performed in this study that was not prospectively specified in the protocol. There was no impact on the overall integrity or conclusions of the study.

Participant flow

Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 01 May 2017. The last study visit occurred on 02 October 2019.

Randomized Treatment Period
Participant flow — Randomized Treatment Period
MilestoneLanraplenibFilgotinibTirabrutinibPlaceboPlacebo to LanraplenibPlacebo to FilgotinibPlacebo to Tirabrutinib
Started38383937000
Completed26293332000
Not completed12965000
Withdrew: Withdrew consent4533000
Withdrew: Adverse event5210000
Withdrew: Investigator's discretion2100000
Withdrew: Protocol violation0111000
Withdrew: Lost to follow-up0010000
Withdrew: Randomized but didn't receive study drug1001000
Placebo Arm Re-Randomized
Participant flow — Placebo Arm Re-Randomized
MilestoneLanraplenibFilgotinibTirabrutinibPlaceboPlacebo to LanraplenibPlacebo to FilgotinibPlacebo to Tirabrutinib
Started0000101210
Completed000010129
Not completed0000001
Withdrew: Withdrew consent0000001

Outcome measures

PrimaryPercentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline

Response was defined as: Improvement ≥ 20% in ≥ 3 of 5 participant-reported Sjogren's syndrome (SjS) related visual analogue score (VAS) measures (participant's assessment of global disease, pain, oral dryness, ocular dryness and fatigue), with no increase defined as \> 30 mm from baseline (Day 1) in any of the above 5 VAS measures, AND either ≥ 20% improvement in high sensitivity C-reactive protein (hsCRP) (if hsCRP ≥ 1.5 x upper limit of normal \[ULN\] on Day 1) or no increase in hsCRP to ≥ 1.5 x ULN (if hsCRP \< 1.5 x ULN on Day 1).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline
percentage of participantsLanraplenibFilgotinibTirabrutinibPlacebo
Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline42.9 (25.0 to 60.7)43.2 (25.9 to 60.6)35.1 (18.4 to 51.9)26.5 (10.2 to 42.8)
Statistical analysis
  • Lanraplenib vs Placebo · Cochran-Mantel-Haenszel · p = 0.1597 (P-values were obtained from Cochran-Mantel-Haenszel (CMH) test stratified by randomization stratification factors.) · Difference in response rates: 15.6 · 95% CI -6.3 to 37.6For the analysis of the difference in response rates, the data with missing response values were imputed by multiple imputation method with logistic regression.
  • Filgotinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.1694 (P-values were obtained from CMH test stratified by randomization stratification factors.) · Difference in response rates: 16.6 · 95% CI -5.1 to 38.3For the analysis of the difference in response rates, the data with missing response values were imputed by multiple imputation method with logistic regression.
  • Tirabrutinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.3309 (P-values were obtained from CMH test stratified by randomization stratification factors.) · Difference in response rates: 8.1 · 95% CI -13.2 to 29.4For the analysis of the difference in response rates, the data with missing response values were imputed by multiple imputation method with logistic regression.
SecondaryChange From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12

The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12
score on a scaleLanraplenibFilgotinibTirabrutinibPlacebo
Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12-2.5 ± 0.76-4.7 ± 0.72-3.2 ± 0.73-3.9 ± 0.76
Statistical analysis
  • Lanraplenib vs Placebo · MMRM · p = 0.2066 · Ls mean difference: 1.3 · 95% CI -0.7 to 3.4
  • Filgotinib vs Placebo · MMRM · p = 0.3998 · Ls mean difference: -0.9 · 95% CI -2.9 to 1.2
  • Tirabrutinib vs Placebo · MMRM · p = 0.5113 · Ls mean difference: 0.7 · 95% CI -1.4 to 2.7
SecondaryChange From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12

The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12
score on a scaleLanraplenibFilgotinibTirabrutinibPlacebo
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12-1.0 ± 0.34-1.4 ± 0.33-1.4 ± 0.33-1.0 ± 0.34
Statistical analysis
  • Lanraplenib vs Placebo · MMRM · p = 0.9446 · Ls mean difference: 0.0 · 95% CI -0.9 to 1.0
  • Filgotinib vs Placebo · MMRM · p = 0.3977 · Ls mean difference: -0.4 · 95% CI -1.3 to 0.5
  • Tirabrutinib vs Placebo · MMRM · p = 0.4966 · Ls mean difference: -0.3 · 95% CI -1.2 to 0.6
SecondaryChange From Baseline in ESSDAI at Week 24

The ESSDAI is a physician-administered tool designed to measure disease activity. It consists of 12 organ-specific 'domains' contributing to disease activity associated with the participant's Sjogren's Syndrome only (constitutional, lymphadenopathy, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological, biological). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. Overall score (ranges from 0 (no activity) to 123 (worst activity)) is calculated as sum of all individual weighted domain scores. A negative change from baseline value indicates improvement.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in ESSDAI at Week 24
score on a scaleLanraplenibFilgotinibTirabrutinibPlacebo
Change From Baseline in ESSDAI at Week 24-4.3 ± 0.81-5.4 ± 0.75-4.0 ± 0.75-4.2 ± 0.78
Statistical analysis
  • Lanraplenib vs Placebo · MMRM · p = 0.9564 · Ls mean difference: -0.1 · 95% CI -2.2 to 2.1
  • Filgotinib vs Placebo · MMRM · p = 0.2788 · Ls mean difference: -1.2 · 95% CI -3.3 to 0.9
  • Tirabrutinib vs Placebo · MMRM · p = 0.8047 · Ls mean difference: 0.3 · 95% CI -1.8 to 2.3
SecondaryChange From Baseline in ESSPRI at Week 24

The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain is scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A negative change from baseline value indicates improvement.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in ESSPRI at Week 24
score on a scaleLanraplenibFilgotinibTirabrutinibPlacebo
Change From Baseline in ESSPRI at Week 24-1.1 ± 0.34-0.8 ± 0.31-1.2 ± 0.31-0.9 ± 0.33
Statistical analysis
  • Lanraplenib vs Placebo · MMRM · p = 0.6782 · Ls mean difference: -0.2 · 95% CI -1.1 to 0.7
  • Filgotinib vs Placebo · MMRM · p = 0.9171 · Ls mean difference: 0.0 · 95% CI -0.8 to 0.9
  • Tirabrutinib vs Placebo · MMRM · p = 0.4641 · Ls mean difference: -0.3 · 95% CI -1.2 to 0.5

Adverse events

Collected over First dose date up to last dose date (Maximum: 50.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lanraplenib0/37 (0%)3/37 (8.1%)30/37 (81.1%)
Filgotinib0/38 (0%)5/38 (13.2%)31/38 (81.6%)
Tirabrutinib0/39 (0%)1/39 (2.6%)32/39 (82.1%)
Placebo to Lanraplenib0/10 (0%)0/10 (0%)10/10 (100%)
Placebo to Filgotinib0/12 (0%)1/12 (8.3%)10/12 (83.3%)
Placebo to Tirabrutinib0/10 (0%)0/10 (0%)7/10 (70%)
Placebo on Placebo Controlled Period0/36 (0%)2/36 (5.6%)23/36 (63.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLanraplenibFilgotinibTirabrutinibPlacebo to LanraplenibPlacebo to FilgotinibPlacebo to TirabrutinibPlacebo on Placebo Controlled Period
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/370/380/390/101/120/100/36
Gastrooesophageal reflux diseaseGastrointestinal disorders0/370/380/390/100/120/101/36
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/370/380/390/100/120/101/36
Acute coronary syndromeCardiac disorders1/370/380/390/100/120/100/36
Pancreatitis acuteGastrointestinal disorders1/370/380/390/100/120/100/36
Suicidal ideationPsychiatric disorders1/370/380/390/100/120/100/36
PancreatitisGastrointestinal disorders0/371/380/390/100/120/100/36
DiverticulitisInfections and infestations0/371/380/390/100/120/100/36
MigraineNervous system disorders0/371/380/390/100/120/100/36
Renal failureRenal and urinary disorders0/371/380/390/100/120/100/36
Most frequent other events
Showing 10 of 82
Most frequent other events
EventLanraplenibFilgotinibTirabrutinibPlacebo to LanraplenibPlacebo to FilgotinibPlacebo to TirabrutinibPlacebo on Placebo Controlled Period
Upper respiratory tract infectionInfections and infestations4/376/389/390/101/120/104/36
FatigueGeneral disorders4/370/383/392/101/120/102/36
Gastroenteritis viralInfections and infestations3/372/383/392/100/120/100/36
NasopharyngitisInfections and infestations3/376/384/391/101/122/104/36
Urinary tract infectionInfections and infestations1/372/384/392/102/120/106/36
Neck painMusculoskeletal and connective tissue disorders0/371/381/392/100/120/100/36
Temporomandibular joint syndromeMusculoskeletal and connective tissue disorders0/371/380/392/100/120/100/36
DiarrhoeaGastrointestinal disorders3/373/383/391/102/120/101/36
ArthralgiaMusculoskeletal and connective tissue disorders4/374/386/390/100/120/100/36
SinusitisInfections and infestations2/371/385/391/100/120/103/36

Baseline characteristics

The Safety Analysis Set included participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)LanraplenibFilgotinibTirabrutinibPlaceboTotal
Mean56.2 ± 9.7252.2 ± 10.5455.8 ± 10.0653.2 ± 10.2854.4 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)LanraplenibFilgotinibTirabrutinibPlaceboTotal
Female36383735146
Male10214
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LanraplenibFilgotinibTirabrutinibPlaceboTotal
Hispanic or Latino641617
Not Hispanic or Latino31343830133
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LanraplenibFilgotinibTirabrutinibPlaceboTotal
American Indian or Alaska Native00011
Asian01102
Black554519
White31323430127
Other10001
Region of Enrollment
Region of Enrollment(participants)LanraplenibFilgotinibTirabrutinibPlaceboTotal
United States26273023106
Poland745622
Spain243413
United Kingdom23139
European League Against Rheumatism (EULAR) Sjogren's syndrome disease activity index (ESSDAI)
European League Against Rheumatism (EULAR) Sjogren's syndrome disease activity index (ESSDAI)(Score on a scale)LanraplenibFilgotinibTirabrutinibPlaceboTotal
Mean10.5 ± 4.8910.2 ± 6.2310.4 ± 5.369.3 ± 3.9610.1 ± 5.16
EULAR Sjogren's syndrome patient reported index (ESSPRI)
EULAR Sjogren's syndrome patient reported index (ESSPRI)(Score on a scale)LanraplenibFilgotinibTirabrutinibPlaceboTotal
Mean6.6 ± 1.906.3 ± 2.315.9 ± 2.395.9 ± 2.246.2 ± 2.22
08

Study locations

53 sites
  • AARR Arizona Arthritis & Rheumatology Research
    Mesa, Arizona 85202, United States
  • AARR Arizona Arthritis & Rheumatology Research
    Phoenix, Arizona 85032, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Omega Research Consultants LLC
    DeBary, Florida 32713, United States
  • Center for Rheumatology Immunology and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34668, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • North Georgia Rheumatology Group, PC
    Lawrenceville, Georgia 30046, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Center for Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • June DO, PC
    Lansing, Michigan 48910, United States
  • North Mississippi Medical Clinics, Inc. - Clinical Research
    Tupelo, Mississippi 38801, United States
  • Clayton Medical Associates
    Saint Louis, Missouri 63117, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • Cape Fear Arthritis Care, PLLC
    Leland, North Carolina 28451, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • East Penn Rheumatology Associates, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading, LLC
    Wyomissing, Pennsylvania 19610, United States
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Ramesh C. Gupta, MD
    Memphis, Tennessee 38119, United States
  • Diagnostic Group Integrated Healthcare System, Pllc
    Beaumont, Texas 77701, United States
  • Accurate Clinical Research Inc.
    Houston, Texas 77034, United States
  • Southwest Rheumatology Research
    Mesquite, Texas 75150, United States
  • Trinity Universal Research Associates
    Plano, Texas 75024, United States
  • Arthritis & Osteoporosis Clinic
    Waco, Texas 76710, United States
  • Wasatch Peak Family Practice
    Layton, Utah 84041, United States
  • The Center for Arthritis and Rheumatic Diseases, PC
    Chesapeake, Virginia 23320, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
  • Centrum Kliniczno-Badawcze
    Elbląg, 82-300, Poland
  • Intermedius
    Kościan, 64-000, Poland
  • Centrum Badan Klinicznych S.C
    Poznan, 60-733, Poland
  • Ai Centrum Medyczne
    Poznan, 61-113, Poland
  • Centrum Medyczne Amed Warszawa Targowek
    Warszawa, 03-921, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital General Universitario De Elche
    Elche, 03203, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, 28942, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29009, Spain
  • Hospital De Merida
    Mérida, 6800, Spain
  • Corporacio Sanitaria Parc Taulí de Sabadell
    Sabadell, 08208, Spain
  • Hospital Clinico Universitario de Salamanca
    San Vicente, 37007, Spain
  • Hospital Quironsalud Infanta Luisa
    Sevilla, 41010, Spain
  • Doncaster Royal Infirmary
    Doncaster, DN2 5LT, United Kingdom
  • Western General Hospital
    Edinburgh, EX4 2XU, United Kingdom
  • Princess Alexandra Hospital
    Harlow, CM20 1QX, United Kingdom
  • Great Western Hospital
    Swindon, SN3 6BB, United Kingdom
  • Warrington Hospital
    Warrington, WA5 1QG, United Kingdom
09

References and documents

Publications

  • Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, Jiang W, Downie B, Mathur A, Mozaffarian A, Mozaffarian N, Gottenberg JE. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 Nov 28;61(12):4797-4808. doi: 10.1093/rheumatology/keac167. PubMed 35377447 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jan 2019, 20 months.

Results were first posted in Jan 2020, 1 year after primary completion.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 4, 2017
StartActual
May 1, 2017
Primary completionActual
Jan 10, 2019
CompletionActual
Oct 2, 2019
Results first posted
Jan 22, 2020
Last update
Oct 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03100942
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
May 1, 2017
Primary completion
Jan 10, 2019
Completion
Oct 2, 2019
Results posted
Jan 22, 2020
Last update
Oct 23, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lanraplenib · GLPG0634 · Tirabrutinib

Start the discussion